Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sirnaomics Ltd. ( (HK:2257) ) has provided an update.
Sirnaomics Ltd. announced its audited consolidated annual results for 2024, highlighting significant progress in its RNAi therapeutics pipeline despite a challenging global economic environment. The company achieved key milestones, including advancements in clinical trials for its STP705 and STP707 programs, and the GalAhead™ platform. Sirnaomics implemented strategic restructuring and cost rationalization to enhance operational efficiency, focusing on high-potential programs and extending its cash runway, positioning itself for sustainable growth.
More about Sirnaomics Ltd.
Sirnaomics Ltd. is a biotechnology company focused on the development of RNA interference (RNAi) therapeutics. The company is engaged in advancing its pipeline of RNAi-based treatments, with a particular emphasis on addressing non-melanoma skin cancer, solid tumors, and coagulation disorders.
YTD Price Performance: 5.78%
Average Trading Volume: 183,398
Technical Sentiment Signal: Buy
Current Market Cap: HK$384.9M
For an in-depth examination of 2257 stock, go to TipRanks’ Stock Analysis page.